1

2

3 “... prophylaxis. It has been shown that almost half of SSIs may be prevented by applying evidence-based strategies...”

4 “... background of adequately controlled pain. More than half of patients with cancer pain likely experience...”

5 “... CF-causing mutation worldwide and approximately half of all Canadian patients with CF are homozygous...”

6 “... background of adequately controlled pain. More than half of patients with cancer pain likely experience...”

7 “... are to control seizures, avoid adverse events (AEs), and maintain or restore quality of life. Approximately half...”

8 “... CF-causing mutation worldwide and approximately half of all Canadian patients with CF are homozygous...”

9 “... and an overdose can be fatal. Buprenorphine also has a long half-life but because it is a partial agonist, it has...”

10 “... activity and long half-life, cyclobenzaprine is not recommended for use in the elderly. The Beers Criteria...”

11 “... are to control seizures, avoid adverse events (AEs), and maintain or restore quality of life. Approximately half...”

12 “... activity and long half-life, cyclobenzaprine is not recommended for use in the elderly. The Beers Criteria...”

13 “... half have one sex chromosome. Mutations of chromosomes in patients with TS lead to a range of clinical...”

14 “... prophylaxis. It has been shown that almost half of SSIs may be prevented by applying evidence-based strategies...”

15 “... suite. It has been reported that one-third to one-half of patients undergoing ERCP under conscious...”

16 “... and an overdose can be fatal. Buprenorphine also has a long half-life but because it is a partial agonist, it has...”

17 “...). Approximately one-half of patients with genotype 1 CHC, the most prevalent type of CHC in Canada, could expect...”

18 “... suite. It has been reported that one-third to one-half of patients undergoing ERCP under conscious...”

19 “...). Approximately one-half of patients with genotype 1 CHC, the most prevalent type of CHC in Canada, could expect...”

20 “... to inhibit viral replication in patients with chronic hepatitis C (CHC). Approximately half of patients...”